Literature DB >> 11072806

Postoperative residual paralysis and respiratory status: a comparative study of pancuronium and vecuronium.

U Bissinger1, F Schimek, G Lenz.   

Abstract

The objective of this prospective double-blind study was to determine whether postoperative residual paralysis (PORP) after pancuronium or vecuronium results in hypoxemia and hypercapnia in the immediate admission period to the recovery ward. Eighty-three consecutive surgical patients received balanced or intravenous anesthesia with pancuronium for operations lasting longer than one hour or vecuronium for those lasting less than 60 min, both combined with neostigmine at the end of anesthesia. Standard clinical criteria assessed neuromuscular function intraoperatively. Postoperatively, we determined neuromuscular function (acceleromyography with supramaximal train-of-four (TOF) stimulation of the ulnar nerve, and a 5-s head lift) and pulmonary function (pulse oximetry: SpO2, and blood gas analysis: SaO2, PaCO2). We defined PORP as a TOF-ratio <70%, hypoxemia as a postoperative SpO2 > or =5% below the pre-anesthestic level together with a postoperative SaO2 <93%, and hypercapnia as a PaCO2 > or =46 mm Hg. Among the 49 pancuronium and 27 vecuronium patients studied, the PORP rates were 20% in the pancuronium group and 7% in the vecuronium group (p>0.05). Hypoxemia and hypercapnia occurred more often in pancuronium patients with PORP than in those without PORP namely 60% vs. 10% (p<0.05) and 30% vs. 8% (p>0.05), respectively. We conclude that PORP after pancuronium is a significant risk factor for hypoxemia.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11072806

Source DB:  PubMed          Journal:  Physiol Res        ISSN: 0862-8408            Impact factor:   1.881


  8 in total

1.  Effective method of continuous rocuronium administration based on effect-site concentrations using a pharmacokinetic/pharmacodynamic model during propofol-remifentanil anesthesia.

Authors:  Takahiro Moriyama; Akira Matsunaga; Osamu Nagata; Kei Enohata; Tomomi Kamikawaji; Erika Uchino; Yuichi Kanmura
Journal:  J Anesth       Date:  2015-03-01       Impact factor: 2.078

2.  Computerized recording of neuromuscular monitoring and the risk of residual paralysis at the time of extubation.

Authors:  Cyrus Motamed; Jean-Louis Bourgain
Journal:  J Clin Monit Comput       Date:  2008-08-07       Impact factor: 2.502

3.  Residual Paralysis: Does it Influence Outcome After Ambulatory Surgery?

Authors:  Hassan Farhan; Ingrid Moreno-Duarte; Duncan McLean; Matthias Eikermann
Journal:  Curr Anesthesiol Rep       Date:  2014-12

4.  [Hypoxemia after general anesthesia].

Authors:  H Aust; L H J Eberhart; P Kranke; C Arndt; C Bleimüller; M Zoremba; D Rüsch
Journal:  Anaesthesist       Date:  2012-04       Impact factor: 1.041

5.  Prevention of Postoperative Events following Reversal with Sugammadex or Neostigmine (the P-PERSoN Trial): Pilot Data Following Early Termination of a Prospective, Blinded, Randomised Trial.

Authors:  Benjamin Olesnicky; Matthew Doane; Clare Farrell; Greg Knoblanche; Anthony Delaney
Journal:  Anesthesiol Res Pract       Date:  2022-07-08

6.  Efficacy and safety of neostigmine for neuromuscular blockade reversal in patients under general anesthesia: a systematic review and meta-analysis.

Authors:  Wentao Ji; Xiaoting Zhang; Jia Liu; Guolin Sun; Xiandong Wang; Lulong Bo; Xiaoming Deng
Journal:  Ann Transl Med       Date:  2021-11

7.  Economic impact of improving patient safety using Sugammadex for routine reversal of neuromuscular blockade in Spain.

Authors:  J Martinez-Ubieto; C Aragón-Benedí; J de Pedro; L Cea-Calvo; A Morell; Y Jiang; S Cedillo; P Ramírez-Boix; A M Pascual-Bellosta
Journal:  BMC Anesthesiol       Date:  2021-02-16       Impact factor: 2.217

8.  Feasibility of full and rapid neuromuscular blockade recovery with sugammadex in myasthenia gravis patients undergoing surgery - a series of 117 cases.

Authors:  Tomas Vymazal; Martina Krecmerova; Vladimír Bicek; Robert Lischke
Journal:  Ther Clin Risk Manag       Date:  2015-10-15       Impact factor: 2.423

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.